Market/Novel Tech Articles
University of Oxford retinal gene therapy company, Nightstar Therapeutics Ltd., files application to float on US NASDAQ.
Nightstar Therapeutics Ltd., a retinal gene therapy company spun out of the University of Oxford, UK, has filed a Form-1 with the United States SEC to raise up to $86.25M in an initial public offering on the NASDAQ Global Market. The company will adopt the symbol “NITE”. In their registration statement to float the company, […]Read full story
AGTC Inc. in Florida files an investigational new drug application for X-linked retinitis pigmentosa
Applied Genetic Technologies Corp. (NASDAQ: AGTC), a gene therapy company based in Gainesville, Florida, has announced the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for its gene therapy product candidate to treat X-linked retinitis pigmentosa (XLRP). The company plans to conduct a Phase I/II clinical trial […]Read full story
GenSight Biologics Inc. reports completion of Phase III enrolment for a gene therapy treatment for Leber’s Hereditary Optic Neuropathy (LHON)
GenSight Biologics Inc., (EURONEXT: SIGHT), Paris, France, have announced that their experimental GS010 treatment for LHON has completed enrollment in the company’s Phase III clinical trial. The Phase III study termed “RESCUE” is one of two parallel randomized, double-masked, controlled, multi-center pivotal trials designed to evaluate the efficacy of a single intravitreal injection of GS010 […]Read full story